Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.
L'homme
Rafaëlla Fa
RF
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands.
Nijland
Hanneke M J
HM
Gras
Luuk
L
Aarnoutse
Rob E
RE
van Crevel
Reinout
R
Boeree
Martin
M
Brinkman
Kees
K
Prins
Jan M
JM
Juttmann
Job R
JR
Burger
David M
DM
D000328:Adult; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D015497:HIV-1; D006801:Humans; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000008:administration & dosage*; D012293:Rifampin / Q000008:administration & dosage*; D019438:Ritonavir / Q000008:administration & dosage*; D019562:Viral Load
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir; D012293:Rifampin